Deep vein thrombosis (DVT), caused by alterations in venous homeostasis, is the third most common cause of cardiovascular mortality, however, key molecular determinants in venous thrombosis have not been fully elucidated. Several lines of evidence indicate that DVT occurs at the intersection of dysregulated inflammation and coagulation. The enzyme ectonucleoside tri(di)phosphohydrolase (ENTPD1, also known as CD39) is a vascular ecto-apyrase on the surface of leukocytes and the endothelium that inhibits intravascular inflammation and thrombosis by hydrolysis of phosphodiester bonds from nucleotides released by activated cells. Here, we evaluated the contribution of CD39 to venous thrombosis in a restricted-flow model of murine inferior vena cava stenosis. CD39 deficiency conferred a greater than 2-fold increase in venous thrombogenesis, characterized by increased leukocyte engagement, neutrophil extracellular trap formation, fibrin, and local activation of tissue factor in the thrombotic milieu. This venous thrombogenesis was orchestrated by increased phosphorylation of the p65 subunit of NF-κB, activation of the NLR family pyrin domain–containing 3 (NLRP3) inflammasome, and IL-1β release in CD39-deficient mice. Substantiating these findings, an IL-1β–neutralizing antibody or the IL-1 receptor inhibitor anakinra attenuated the thrombosis risk in CD39-deficient mice. These data demonstrate that IL-1β is a key accelerant of venous thrombo-inflammation, which can be suppressed by CD39. CD39 inhibits in vivo crosstalk between inflammation and coagulation pathways and is a critical vascular checkpoint in […]

Find the latest version:

http://jci.me/124804/pdf
ENTPD-1 disrupts inflammasome IL-1β–driven venous thrombosis

Vinita Yadav,1 Liguo Chi,1 Raymond Zhao,1 Benjamin E. Tourdot,2 Srilakshmi Yalavarthi,3 Benjamin N. Jacobs,4 Alison Banka,1,5 Hui Liao,1 Sharon Koong,1 Anuli C. Anyanwu,1,4 Scott H. Visovati,1 Michael A. Holinstat,2 J. Michelle Kahlenberg,3 Jason S. Knight,3 David J. Pinsky,1,6 and Yogendra Kanthi1,7

1Division of Cardiovascular Medicine, Frankel Cardiovascular Center, 2Department of Pharmacology, 3Division of Rheumatology, and 4Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA. 5Department of Chemical Engineering, University of Michigan College of Engineering, Ann Arbor, Michigan, USA. 6Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, USA. 7Section of Cardiology, Ann Arbor Veterans Health System, Ann Arbor, Michigan, USA.

The cell-surface enzyme ectonucleoside tri(di)phosphohydrolase (ENTPD1), also known as CD39), is a vascular ecto-apyrase on the surface of leukocytes and the endothelium that inhibits intravascular inflammation and thrombosis by hydrolysis of phosphodiester bonds from nucleotides released by activated cells. Here, we evaluated the contribution of CD39 to venous thrombosis in a restricted-flow model of murine inferior vena cava stenosis. CD39 deficiency conferred a greater than 2-fold increase in venous thrombogenesis, characterized by increased leukocyte engagement, neutrophil extracellular trap formation, fibrin, and local activation of tissue factor in the thrombotic milieu. This venous thrombogenesis was orchestrated by increased phosphorylation of the p65 subunit of NF-κB, activation of the NLR family pyrin domain–containing 3 (NLRP3) inflammasome, and IL-1β release in CD39-deficient mice. Substantiating these findings, an IL-1β–neutralizing antibody or the IL-1 receptor inhibitor anakinra attenuated the thrombosis risk in CD39-deficient mice. These data demonstrate that IL-1β is a key accelerant of venous thrombo-inflammation, which can be suppressed by CD39. CD39 inhibits in vivo crosstalk between inflammation and coagulation pathways and is a critical vascular checkpoint in venous thrombosis.

Deep vein thrombosis (DVT), caused by alterations in venous homeostasis, is the third most common cause of cardiovascular mortality, however, key molecular determinants in venous thrombosis have not been fully elucidated. Several lines of evidence indicate that DVT occurs at the intersection of dysregulated inflammation and coagulation. The enzyme ectonucleoside tri(di)phosphohydrolase (ENTPD1, also known as CD39) is a vascular ecto-apyrase on the surface of leukocytes and the endothelium that inhibits intravascular inflammation and thrombosis by hydrolysis of phosphodiester bonds from nucleotides released by activated cells. Here, we evaluated the contribution of CD39 to venous thrombosis in a restricted-flow model of murine inferior vena cava stenosis. CD39 deficiency conferred a greater than 2-fold increase in venous thrombogenesis, characterized by increased leukocyte engagement, neutrophil extracellular trap formation, fibrin, and local activation of tissue factor in the thrombotic milieu. This venous thrombogenesis was orchestrated by increased phosphorylation of the p65 subunit of NF-κB, activation of the NLR family pyrin domain–containing 3 (NLRP3) inflammasome, and IL-1β release in CD39-deficient mice. Substantiating these findings, an IL-1β–neutralizing antibody or the IL-1 receptor inhibitor anakinra attenuated the thrombosis risk in CD39-deficient mice. These data demonstrate that IL-1β is a key accelerant of venous thrombo-inflammation, which can be suppressed by CD39. CD39 inhibits in vivo crosstalk between inflammation and coagulation pathways and is a critical vascular checkpoint in venous thrombosis.

Deep vein thrombosis (DVT), caused by alterations in venous homeostasis, is the third most common cause of cardiovascular mortality, however, key molecular determinants in venous thrombosis have not been fully elucidated. Several lines of evidence indicate that DVT occurs at the intersection of dysregulated inflammation and coagulation. The enzyme ectonucleoside tri(di)phosphohydrolase (ENTPD1, also known as CD39) is a vascular ecto-apyrase on the surface of leukocytes and the endothelium that inhibits intravascular inflammation and thrombosis by hydrolysis of phosphodiester bonds from nucleotides released by activated cells. Here, we evaluated the contribution of CD39 to venous thrombosis in a restricted-flow model of murine inferior vena cava stenosis. CD39 deficiency conferred a greater than 2-fold increase in venous thrombogenesis, characterized by increased leukocyte engagement, neutrophil extracellular trap formation, fibrin, and local activation of tissue factor in the thrombotic milieu. This venous thrombogenesis was orchestrated by increased phosphorylation of the p65 subunit of NF-κB, activation of the NLR family pyrin domain–containing 3 (NLRP3) inflammasome, and IL-1β release in CD39-deficient mice. Substantiating these findings, an IL-1β–neutralizing antibody or the IL-1 receptor inhibitor anakinra attenuated the thrombosis risk in CD39-deficient mice. These data demonstrate that IL-1β is a key accelerant of venous thrombo-inflammation, which can be suppressed by CD39. CD39 inhibits in vivo crosstalk between inflammation and coagulation pathways and is a critical vascular checkpoint in venous thrombosis.

Introduction

The cell-surface enzyme ectonucleoside tri(di)phosphohydrolase-1 (ENTPD1), also known as CD39), is a key molecular factor protecting blood fluidity at the vessel-wall interface by catalyzing the hydrolytic cleavage of phosphodiester bonds, thereby dissipating the extracellular purinergic nucleotides ATP and ADP. These extracellular purines function as intravascular autocrine and paracrine “danger” signals to a variety of cells including innate immune cells, platelets, and endothelium, activating inflammatory and thrombotic pathways (1, 2). Our group has recently shown that CD39 haploinsufficiency is a critical mediator of arterial leukocyte trafficking, atherosclerosis, and platelet hyperactivity (3–5), but the role for CD39 in the venous milieu has not been fully elucidated. In contrast to arterial beds, veins are characterized by low shear, an absence of atherosclerotic plaque, and an emphasis on tissue factor–driven thrombosis. Despite the substantial morbidity and mortality burden of deep vein thrombosis (DVT) (6), proximate mechanisms that trigger and propagate venous thrombosis are incompletely understood. As a window to understanding venous thrombus pathogenesis, many acquired risk factors are associated with DVT, including trauma, infection, and chronic inflammatory diseases, suggesting an integral association between inflammation and coagulation (7). Although multiple, sometimes coalescing, pathologic drivers can result in venous thrombosis, current studies have largely focused on coagulation, while the precise mechanisms underlying inflammatory triggers and their endogenous checkpoints remain unknown. We hypothesized that CD39-haploinsufficient mice would have impaired protection against DVT, enhanced leukocyte recruitment and activation, and unrestrained inflammatory signaling.

Here, we show that CD39 plays a critical role in protection from venous thrombogenesis in restricted venous flow conditions by checking leukocyte engagement and inflammasome activation. Our data show that loss of a single Cd39 allele increases venous thrombosis and propagation, with enhanced tissue factor and fibrin deposition, neutrophil extracellular trap (NET) formation, and canonical inflammasome activation, under control of NF-κB, the NOD-like receptor pyrin domain–containing 3 protein (NLRP3) inflammasome, and IL-1β expression. Taken together,
these data provide evidence that CD39 serves as an indispensable checkpoint of venous inflammation and coagulation at the blood-vessel interface by restraining innate immune activation.

Results and Discussion

CD39 protects against venous thrombosis following inferior vena cava flow restriction. Our group and others have previously shown that CD39 has a potent antithrombotic and antiinflammatory effect in the context of arterial flow conditions (3, 4, 8). We first validated our model of flow-restricted venous thrombosis in mice with a normal complement of CD39 (WT), with thrombus occurring in 23% of mice (Figure 1A), consistent with prior reports in this model (9–11). These thrombi contained regions that were RBC rich and RBC poor, similar to the morphology seen in human venous thrombi (12). Given that expression of CD39 can be dynamically downregulated by systemic cytotoxic stress or local turbulent blood flow patterns and that it is being studied as an inhibition target in cancer, we investigated whether partial deficiency of CD39 could contribute to venous thrombosis under flow-restricted conditions. We used CD39-haploinsufficient mice to test the effect of CD39 deficiency on venous thrombosis. Cd39+/− mice have similar circulating leukocyte, RBC, and platelet counts when compared with those of genotype controls (WT) containing the nonexcised LoxP sites used to generate the Cd39+/− mice (13). When subjected to inferior vena cava (IVC) flow restriction, Cd39+/− mice developed significantly more venous thrombosis compared with WT controls (Figure 1A), coupled with more thrombus propagation, sometimes extending into the iliac veins (Figure 1, B and C). As activation of the coagulation cascade results in thrombin-induced cleavage of fibrinogen to fibrin, we examined the effect of CD39 haploinsufficiency on fibrin formation in the venous thrombus milieu. Using a fibrin-specific antibody, we determined that Cd39+/− mice had greater fibrin accumulation than did WT mice, suggesting an increase in the insoluble fibrin networks in the vein lumen that contributed to heightened thrombus stabilization in Cd39+/− mice (Figure 1D). Whether the increased fibrin content in venous thrombi from Cd39+/− mice reflects greater fibrin deposition or deficient fibrinolysis is unknown and remains to be elucidated. Tissue factor, a significant determinant of thrombus initiation and propagation, is released by hematopoietic cells under venous flow-restricted conditions and complexes with factor VII/VIIa in blood to activate the tissue factor (extrinsic) coagulation pathway (14). Consistent with our findings of increased venous thrombogenesis, thrombus lysate from Cd39+/− mice contained more tissue factor when compared with WT controls (Figure 1E).

CD39 haploinsufficiency increases NET formation in venous thrombosis. We next examined whether the increased thrombogenesis in Cd39+/− mice could in part be explained by leukocyte engagement. Venous thrombi in Cd39+/− mice revealed enhanced leukocyte recruitment, driven primarily by neutrophils (Figure 2, A and B). Neutrophil activation with chromatin deconden-
fold increase in expression of a citrullinated form of histone H3 (H3-cit), which is a NET-associated histone modification that results in loosened chromatin structures that can be extruded as NETs (Figure 2C). Consistent with these in vitro findings, immunoblots of venous thrombus lysate from Cd39+/– mice also showed significantly higher levels of H3-cit expression than the levels seen in WT mice (Figure 2D and Supplemental Figure 1B). Confirming the role of neutrophil CD39 haploinsufficiency in promoting thrombosis, Cd39+/– neutrophils administered to WT mice increased thrombus size compared with administration of WT neutrophils (Figure 2E). Taken together, these data suggest that during venous thrombogenesis, CD39 is an obligatory restraint on H3-cit–positive NET formation in vitro and in vivo.

Exaggerated inflammasome activation in venous thrombosis in CD39-deficient mice. Extracellular release of ATP and ADP through cell death, injury, or activation is a potent stress response, altering the local microenvironment to activate paracrine and autocrine signaling pathways (18, 19). Binding of
extracellular ATP to the plasma membrane receptor ionophore P2X7 activates a potent stress-response–signaling pathway characterized by potassium efflux, which triggers assembly and activity of the inflammasome, a multiprotein oligomer that activates highly proinflammatory cytokines including IL-1β (20). Gupta et al. recently reported increased NLRP3 inflammasome assembly in patients at high altitude at risk for DVT (21). Canonical inflammasome activation requires a “priming” step marked by NF-κB activation and inflammasome component transcription (20). A second signal initiates NLRP3-mediated assembly and oligomerization of inflammasome component fibers, proteolytic cleavage of pro–caspase-1 to caspase-1 to generate mature IL-1β, and release of prothrombotic tissue factor–rich microparticles (22, 23). As ATP, the substrate for the phosphohydrolytic activity of CD39, is the primary activating ligand for the vascular P2X7 receptor (24), we hypothesized that CD39 could suppress inflammasome activation in venous thrombosis and that haploinsufficiency would thus drive a proinflammatory state. We examined the expression of NLRP3 inflammasome components in venous thrombi from Cd39+/– and WT mice and observed markedly enhanced phosphorylation of the transactivator serine 534 site (murine homolog of human serine 536) of the NF-κB p65 subunit in Cd39+/– thrombi (Supplemental Figure 2A). This was accompanied by increased expression of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC), and active caspase-1 in Cd39+/– mice (Figure 3, A–C, and Supplemental Figure 2B), as well as exaggerated mature (processed) IL-1β content (Figure 3D) compared with WT thrombi. Concordant with these data, we detected elevated plasma levels of IL-1β in Cd39+/– mice compared with levels in WT mice following venous thrombosis (Figure 3E). A recent large clinical trial demonstrated reduced arterial cardiovascular events in high-risk patients following treatment with a monoclonal antibody targeting IL-1β (25). To determine whether the exaggerated venous thrombosis conferred by CD39 haploinsufficiency could be rescued by reduced IL-1β bioavailability, we next...
performed IVC flow restriction in WT and $Cd39^{-/-}$ mice treated with an IL-1β-neutralizing antibody (Figure 4, A and B). IL-1β blockade resulted in a striking decrease in venous thrombogenesis in $Cd39$-deficient mice; specifically, $Cd39^{-/-}$ mice treated with a neutralizing IL-1β antibody developed smaller and fewer venous thrombi than did isotype IgG-injected $Cd39^{-/-}$ mice under flow-restricted conditions, whereas WT mice treated with neutralizing IL-1β antibody had rates of thrombogenesis similar to those of IgG controls and a nonsignificant decrease in thrombus size. IL-1β blockade did not prolong the tail bleeding time (data not shown). To exclude an IgG-dependent effect of IL-1β blockade on $Cd39^{-/-}$ venous thrombosis, $Cd39^{-/-}$ mice were next treated with anakinira, a synthetic inhibitor of the IL-1 receptor, or saline vehicle control. Concordant with IL-1β neutralization experiments, IL-1 receptor inhibition resulted in lower thrombotic burden than was observed in saline-treated $Cd39^{-/-}$ mice in contemporaneous experiments (Figure 4C). Taken together, these experiments show a pivotal role for $Cd39$, the dominant vascular ectonucleotidase, in inhibiting NLRP3 inflammasome activation and IL-1β signaling during venous thrombogenesis.

In summary, our findings demonstrate for the first time to our knowledge that inflammasome-mediated IL-1β is essential for venous thrombogenesis under vascular conditions which include limited flow. These data also reveal an indispensable role for vascular $Cd39$ in protecting against venous thrombogenesis, as it alters multiple aspects of venous clot formation. A functional paradigm exists, wherein venous thrombosis develops as a convergence of multiple inputs from several cell lineages, including neutrophils, monocytes, platelets, and endothelial cells. In addition to prothrombotic and proinflammatory mediators, these vascular and innate immune effector cells possess the machinery for inflammasome activation and IL-1β processing (14, 20, 26). Our data show that $Cd39$ is vital for reducing intravascular fibrin deposition, which otherwise provides mechanical and structural support to nascent thrombi; for restraining NET formation; for NLRP3 inflammasome activation; and, critically, for IL-1β accessibility during venous thrombosis. IL-1β may facilitate venous thrombosis through several effector mechanisms in the thrombotic milieu including leukocyte recruitment (27, 28), remote signaling via thrombogenic microparticles (23), and platelet integrin activation (29). Indeed, platelets in $Cd39^{-/-}$ mice are also hyperactive (4), suggesting that $Cd39$-based targeted therapeutics may be effective in interrupting a positive feedback loop of thromboinflammation (5, 30). Taken together, these data present a compelling role for $Cd39$ as a vascular checkpoint in impeding venous thrombus accretion. Treatments for venous thrombosis have largely targeted the coagulation pathway, leading to incomplete protection from DVT. Strategies aimed at the nexus of inflammation and coagulation will be critical for progress in the development of effective therapeutics in venous thrombosis.

Methods

Detailed Methods are provided in the Supplemental Methods.

Statistics. Data analysis was performed using GraphPad Prism 8 software. Normally distributed data were analyzed using an unpaired, 2-tailed Student’s $t$ test, and skewed data were analyzed using Welch’s correction. Thrombus frequency was analyzed by $\chi^2$ analysis. Statistical significance was defined as a $P$ value of less than 0.05.

Study approval. All experiments were conducted in accordance with NIH guidelines for the use of live animals and were approved by the IACUC of the University of Michigan.

Author contributions

YK and DJP were responsible for the study concept and design. YK, VY, LC, AB, RZ, HL, BNJ, SY, and BET acquired data. YK, VY, LC, AB, RZ, HL, and BET performed data analysis. YK, BET, DJP, JSK, JMK, SHV, MAH, and ACA interpreted the data. SK and HL were responsible for mouse strain generation and colony management. YK and DJP supervised the study, obtained funding, and drafted the manuscript.

Acknowledgments

The authors would like to thank Cathy Luke, Peter Henke, and Gabriel Nunez (University of Michigan) for helpful discussions. The authors also acknowledge members of the University of Michigan Dental School Histology Core. This work was supported in part by funding from the following: the NIH (K08HL131993, to YK; T32HL007853, to BNJ and ACA; HL127151 and NS087147, to DJP; GM105671 and HL114405, to MH; K99HL156784, to BET; HL134846, to JSK; AR072107, to JMK; and HL119623, to SHV); a J. Griswold Ruth MD and Margery Hopkins Ruth Professorship; the Haller Family Foundation; the A. Alfred Taubman Medical Research Institute (to DJP); a McKay Grant; the Bo Schembecher Heart of a Champion Foundation; the Jobst-American Venous Forum Foundation (to YK); and the University of Michigan Frankel Cardiovascular Center.

Address correspondence to: Yogendra Kanthi, Division of Cardiovascular Medicine, Department of Internal Medicine, 2344 Frankel Cardiovascular Center, 1150 E. Medical Center Drive, SPC 5853, Ann Arbor, Michigan 48109-5853, USA. Phone: 734.998.7955; Email: ykanthi@umich.edu.


